ChemicalBook > Product Catalog >API >Antipyretic analgesics >Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) >Hydrazinecarboximidamide, 2-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-2-propen-1-ylidene]-, acetate (1:1), (2E)-

Hydrazinecarboximidamide, 2-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-2-propen-1-ylidene]-, acetate (1:1), (2E)-

Hydrazinecarboximidamide, 2-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-2-propen-1-ylidene]-, acetate (1:1), (2E)- Basic information
Product Name:Hydrazinecarboximidamide, 2-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-2-propen-1-ylidene]-, acetate (1:1), (2E)-
Synonyms:Hydrazinecarboximidamide, 2-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-2-propen-1-ylidene]-, acetate (1:1), (2E)-
CAS:1809420-72-1
MF:C16H18N6O4
MW:358.36
EINECS:
Product Categories:
Mol File:1809420-72-1.mol
Hydrazinecarboximidamide, 2-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-2-propen-1-ylidene]-, acetate (1:1), (2E)- Structure
Hydrazinecarboximidamide, 2-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-2-propen-1-ylidene]-, acetate (1:1), (2E)- Chemical Properties
form Solid
color Yellow to brown
Safety Information
MSDS Information
Hydrazinecarboximidamide, 2-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-2-propen-1-ylidene]-, acetate (1:1), (2E)- Usage And Synthesis
UsesResomelagon (AP1189) acetate is a potent, orally active melanocortin receptor (MR) agonist about MC1 and MC3. Resomelagon acetate induces ERK1/2 phosphorylation and Ca2+ mobilization. Resomelagon acetate has anti-inflammatory activity. Resomelagon acetate can be used for obesity and chronic inflammation research[1][2].
in vivo

Resomelagon acetate (0-10 mg/kg; i.p., i.v. and p.o.; for 24 h; male C57BL/6J wild-type (WT) and BALB/c mice) promotes resolution of acute inflammation in vivo[1].
Resomelagon acetate (25-50 mg/kg; p.o.; daily, for 8 d; male C57BL/6J wild-type (WT) and BALB/c mice) reduces arthritis in mice[1].

References[1] Montero-Melendez T, et, al. Biased agonism as a novel strategy to harness the proresolving properties of melanocortin receptors without eliciting melanogenic effects. J Immunol. 2015 Apr 1;194(7):3381-8. DOI:10.4049/jimmunol.1402645
[2] WHO Drug Information. International Nonproprietary Names for Pharmaceutical.
Hydrazinecarboximidamide, 2-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-2-propen-1-ylidene]-, acetate (1:1), (2E)- Preparation Products And Raw materials
Tag:Hydrazinecarboximidamide, 2-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-2-propen-1-ylidene]-, acetate (1:1), (2E)-(1809420-72-1) Related Product Information
Hydrazinecarboximidamide, 2-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-2-propen-1-ylidene]-, (2E)- Hydrazinecarboximidamide, 2-[(2E)-3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-2-propen-1-ylidene]-, acetate (1:1), (2E)- AP1189 acetate BETA-MSH, HUMAN D-Prolinamide, N-acetyl-L-norleucyl-L-α-aspartyl-L-prolyl-3-(2-naphthalenyl)-D-alanyl-L-arginyl-L-tryptophyl-L-lysyl-D-valyl-, (2→7)-lactam ALPHA-MSH